{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:37:25Z","timestamp":1769769445575,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clinthera.2012.06.022","type":"journal-article","created":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T20:07:02Z","timestamp":1342210022000},"page":"1816-1826","source":"Crossref","is-referenced-by-count":35,"title":["ABCB1 C3435T Genetic Polymorphism on Population Pharmacokinetics of Methotrexate After Hematopoietic Stem Cell Transplantation in Korean Patients: A Prospective Analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"In-Wha","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwi-yeol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon-Yang","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.06.022_bib1","first-page":"113","article-title":"Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy","volume":"7","author":"Aschan","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2012.06.022_bib2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood.V81.4.1094.1094","article-title":"Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?","volume":"81","author":"Ringden","year":"1993","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.06.022_bib3","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.bbmt.2009.10.016","article-title":"Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?","volume":"16","author":"Storb","year":"2010","journal-title":"J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2012.06.022_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1056\/NEJM199103073241005","article-title":"Graft-versus-host disease","volume":"324","author":"Ferrara","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.022_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2012.06.022_bib6","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood.V94.11.3941","article-title":"Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants","volume":"94","author":"Cavet","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.06.022_bib7","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa022060","article-title":"Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation","volume":"349","author":"Lin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.022_bib8","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-04-1033","article-title":"Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation","volume":"100","author":"Rocha","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.06.022_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00007890-200108270-00024","article-title":"Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"72","author":"Socie","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2012.06.022_bib10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.V73.6.1729.1729","article-title":"Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial","volume":"73","author":"Storb","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.06.022_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.022_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate: new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.06.022_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00262416","article-title":"Pharmacokinetic monitoring of high-dose methotrexate","volume":"3","author":"Evans","year":"1979","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM198602203140803","article-title":"Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia","volume":"314","author":"Evans","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.022_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(84)90411-2","article-title":"Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia","volume":"1","author":"Evans","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.06.022_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.022_bib17","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1016\/S0021-9258(18)91984-8","article-title":"Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell","volume":"243","author":"Goldman","year":"1968","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2012.06.022_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate","volume":"76","author":"Chabner","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2012.06.022_bib19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199610033351408","article-title":"Intrinsic and acquired resistance to methotrexate in acute leukemia","volume":"335","author":"Gorlick","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.022_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0163-7258(99)00063-7","article-title":"Glutamyl hydrolase. pharmacological role and enzymatic characterization","volume":"85","author":"Galivan","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.06.022_bib21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0026-895X(24)13274-9","article-title":"Characterization of human cellular gamma-glutamyl hydrolase","volume":"53","author":"Rhee","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib22","doi-asserted-by":"crossref","first-page":"10134","DOI":"10.1073\/pnas.93.19.10134","article-title":"Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro","volume":"93","author":"Yao","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2012.06.022_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-002-0511-x","article-title":"A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia","volume":"50","author":"Panetta","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/138920011795101840","article-title":"Clinical pharmacogenetics of methotrexate","volume":"12","author":"Castaldo","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2012.06.022_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.clinthera.2012.06.022_bib27","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jpba.2006.12.034","article-title":"Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry","volume":"43","author":"Guo","year":"2007","journal-title":"J Pharm Biomed Analysis"},{"key":"10.1016\/j.clinthera.2012.06.022_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2013an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clinthera.2012.06.022_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clinthera.2012.06.022_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clinthera.2012.06.022_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pbc.10443","article-title":"Methotrexate pharmacokinetics and survival in osteosarcoma","volume":"42","author":"Aquerreta","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clinthera.2012.06.022_bib32","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/cncr.20152","article-title":"High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma","volume":"100","author":"Crews","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.06.022_bib33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1472-8206.1999.tb00366.x","article-title":"Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach","volume":"13","author":"Odoul","year":"1999","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003088-200241130-00006","article-title":"Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma","volume":"41","author":"Rousseau","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.06.022_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.leu.2401673","article-title":"Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia","volume":"14","author":"Wall","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.06.022_bib36","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2012.06.022_bib37","series-title":"Pharmacokinetics in Drug Development: Clinical Study Design and Analysis","author":"Bonate","year":"2004"},{"key":"10.1016\/j.clinthera.2012.06.022_bib38","series-title":"Concepts in Pharmacogenomics","author":"Zdanowicz","year":"2010"},{"key":"10.1016\/j.clinthera.2012.06.022_bib39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","article-title":"Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia","volume":"45","author":"Aumente","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.06.022_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1703616","article-title":"Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease","volume":"30","author":"Kumar","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2012.06.022_bib41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0959-8049(02)00024-2","article-title":"Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"38","author":"Batey","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2012.06.022_bib42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0b013e3181945624","article-title":"Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma","volume":"31","author":"Colom","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2012.06.022_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-199310000-00004","article-title":"Pharmacokinetic interaction between high-dose methotrexate and amoxycillin","volume":"15","author":"Ronchera","year":"1993","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2012.06.022_bib44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/106002809703101022","article-title":"Delayed elimination of methotrexate associated with piperacillin administration","volume":"31","author":"Yamamoto","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.022_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","article-title":"Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma","volume":"67","author":"Faganel Kotnik","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","article-title":"High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations","volume":"80","author":"Rau","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.06.022_bib47","first-page":"83","article-title":"Detection of tumour antigens in sera of patients with hepatocellular carcinoma using monoclonal antibodies","volume":"8","author":"Wong","year":"1990","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib48","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood.V81.9.2394.2394","article-title":"Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications","volume":"81","author":"Goasguen","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.06.022_bib49","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":"Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2012.06.022_bib50","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-003-0567-5","article-title":"Digoxin pharmacokinetics and MDR1 genetic polymorphisms","volume":"58","author":"Verstuyft","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2125.2002.01691.x","article-title":"MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males","volume":"54","author":"Gerloff","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270003253617","article-title":"The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients","volume":"43","author":"Yates","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib53","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2146\/ajhp080396","article-title":"Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients","volume":"66","author":"Bonhomme-Faivre","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2012.06.022_bib54","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/00007890-200212150-00002","article-title":"Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement","volume":"74","author":"Macphee","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2012.06.022_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00043426-199221000-00014","article-title":"Possible methotrexate-mezlocillin interaction","volume":"14","author":"Dean","year":"1992","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s002800050840","article-title":"Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate","volume":"42","author":"Najjar","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.022_bib57","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2010-01-256958","article-title":"The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number","volume":"115","author":"Gregers","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:28:26Z","timestamp":1743730106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812003852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0149291812003852"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}